Shigeyuki Chaki

Shigeyuki Chaki publication distribution in Neuroscience in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Neuroscience in 2026. The highlighted bar marks where Shigeyuki Chaki sits on this spectrum.

Shigeyuki Chaki D-index placement in Neuroscience in 2026

The chart shows the D-index (discipline H-index) distribution of Neuroscience scientists ranked by Research.com in 2026. The highlighted bar marks where Shigeyuki Chaki sits on this spectrum.

Best Publications

• Involvement of AMPA receptor in both the rapid and sustained antidepressant-like effects of ketamine in animal models of depression

  Hiroyuki Koike;Michihiko Iijima;Shigeyuki Chaki

  448
  Citations

• MGS0039: a potent and selective group II metabotropic glutamate receptor antagonist with antidepressant-like activity.

  Shigeyuki Chaki;Ryoko Yoshikawa;Shiho Hirota;Toshiharu Shimazaki

  356
  Citations

• Neurochemistry of the Nucleus Accumbens and its Relevance to Depression and Antidepressant Action in Rodents

  Yukihiko Shirayama;Shigeyuki Chaki

  282
  Citations

• Antidepressant Potential of (R)-Ketamine in Rodent Models: Comparison with (S)-Ketamine.

  Kenichi Fukumoto;Hidetoh Toki;Michihiko Iijima;Takashi Hashihayata

  248
  Citations

• Mood disorders: regulation by metabotropic glutamate receptors.

  Andrzej Pilc;Shigeyuki Chaki;Gabriel Nowak;Jeffrey M. Witkin

  217
  Citations

• Design, synthesis and structure-affinity relationships of aryloxyanilide derivatives as novel peripheral benzodiazepine receptor ligands.

  Taketoshi Okubo;Ryoko Yoshikawa;Shigeyuki Chaki;Shigeru Okuyama

  215
  Citations

• The Antidepressant Effects of an mGlu2/3 Receptor Antagonist and Ketamine Require AMPA Receptor Stimulation in the mPFC and Subsequent Activation of the 5-HT Neurons in the DRN.

  Kenichi Fukumoto;Michihiko Iijima;Shigeyuki Chaki

  209
  Citations

• D-Serine and a glycine transporter inhibitor improve MK-801-induced cognitive deficits in a novel object recognition test in rats.

  Jun-ichi Karasawa;Kenji Hashimoto;Shigeyuki Chaki

  203
  Citations

• Requirement of AMPA receptor stimulation for the sustained antidepressant activity of ketamine and LY341495 during the forced swim test in rats

  Hiroyuki Koike;Shigeyuki Chaki

  199
  Citations

• An mGluR2/3 antagonist, MGS0039, exerts antidepressant and anxiolytic effects in behavioral models in rats

  Takao Yoshimizu;Toshiharu Shimazaki;Akie Ito;Shigeyuki Chaki

  184
  Citations

• AMPA receptor stimulation mediates the antidepressant-like effect of a group II metabotropic glutamate receptor antagonist

  Jun-ichi Karasawa;Toshiharu Shimazaki;Naoya Kawashima;Shigeyuki Chaki

  180
  Citations

• (R)-Ketamine Shows Greater Potency and Longer Lasting Antidepressant Effects Than Its Metabolite (2R,6R)-Hydroxynorketamine

  Chun Yang;Youge Qu;Masahito Abe;Dai Nozawa

  178
  Citations

• Anxiolytic- and Antidepressant-Like Profile of ATC0065 and ATC0175: Nonpeptidic and Orally Active Melanin-Concentrating Hormone Receptor 1 Antagonists

  Shigeyuki Chaki;Takeo Funakoshi;Shiho Hirota-Okuno;Mariko Nishiguchi

  174
  Citations

• Synthesis, SARs, and pharmacological characterization of 2-amino-3 or 6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivatives as potent, selective, and orally active group II metabotropic glutamate receptor agonists.

  Atsuro Nakazato;Toshihito Kumagai;Kazunari Sakagami;Ryoko Yoshikawa

  172
  Citations

• Anxiolytic-Like and Antidepressant-Like Activities of MCL0129 (1-[(S)-2-(4-Fluorophenyl)-2-(4-isopropylpiperadin-1-yl)ethyl]-4-[4-(2-methoxynaphthalen-1-yl)butyl]piperazine), a Novel and Potent Nonpeptide Antagonist of the Melanocortin-4 Receptor

  Shigeyuki Chaki;Shiho Hirota;Takeo Funakoshi;Yoshiko Suzuki

  170
  Citations

• Increased cell proliferation in the adult mouse hippocampus following chronic administration of group II metabotropic glutamate receptor antagonist, MGS0039.

  Takao Yoshimizu;Shigeyuki Chaki

  170
  Citations

• Anxiety-like behavior in mice lacking the angiotensin II type-2 receptor

  Shigeru Okuyama;Takashi Sakagawa;Shigeyuki Chaki;Yasuko Imagawa

  167
  Citations

• Involvement of the mammalian target of rapamycin signaling in the antidepressant-like effect of group II metabotropic glutamate receptor antagonists

  Hiroyuki Koike;Michihiko Iijima;Shigeyuki Chaki

  162
  Citations

• Involvement of melanocortin-4 receptor in anxiety and depression.

  Shigeyuki Chaki;Shigeru Okuyama

  155
  Citations

• Anxiolytic- and antidepressant-like profile of a new CRF1 receptor antagonist, R278995/CRA0450.

  Shigeyuki Chaki;Atsuro Nakazato;Ludo Kennis;Masato Nakamura

  147
  Citations